Diagnostic accuracy and feasibility of patient self-testing with a SARS-CoV-2 antigen-detecting rapid test. by Lindner, Andreas K et al.
 
 
Since January 2020 Elsevier has created a COVID-19 resource centre with 
free information in English and Mandarin on the novel coronavirus COVID-
19. The COVID-19 resource centre is hosted on Elsevier Connect, the 
company's public news and information website. 
 
Elsevier hereby grants permission to make all its COVID-19-related 
research that is available on the COVID-19 resource centre - including this 
research content - immediately available in PubMed Central and other 
publicly funded repositories, such as the WHO COVID database with rights 
for unrestricted research re-use and analyses in any form or by any means 
with acknowledgement of the original source. These permissions are 
granted for free by Elsevier for as long as the COVID-19 resource centre 
remains active. 
 
Journal of Clinical Virology 141 (2021) 104874
Available online 29 May 2021
1386-6532/© 2021 Elsevier B.V. All rights reserved.
Short Communication 
Diagnostic accuracy and feasibility of patient self-testing with a 
SARS-CoV-2 antigen-detecting rapid test 
Andreas K. Lindner a,#,*, Olga Nikolai a,#, Chiara Rohardt a, Franka Kausch a, Mia Wintel a, 
Maximilian Gertler a, Susen Burock b, Merle Hörig a, Julian Bernhard a, Frank Tobian c, 
Mary Gaeddert c, Federica Lainati c, Victor M. Corman d,e, Terry C. Jones d,e,f, Jilian A. Sacks g, 
Joachim Seybold h, Claudia M. Denkinger c,i,#, Frank P. Mockenhaupt a,# 
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1, 10117 Berlin, Germany 
c Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Im Neuenheimer Feld 672, 69120 Heidelberg, Germany 
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A B S T R A C T   
Background: Considering the possibility of nasal self-sampling and the ease of use in performing SARS-CoV-2 
antigen-detecting rapid diagnostic tests (Ag-RDTs), self-testing is a feasible option. 
Objective: The goal of this study was a head-to-head comparison of diagnostic accuracy of patient self-testing with 
professional testing using a SARS-CoV-2 Ag-RDT. 
Study design: We performed a manufacturer-independent, prospective diagnostic accuracy study of nasal mid- 
turbinate self-sampling and self-testing with symptomatic adults using a WHO-listed SARS-CoV-2 Ag-RDT. 
Procedures were observed without intervention. For comparison, Ag-RDTs with nasopharyngeal sampling 
were professionally performed. Estimates of agreement, sensitivity, and specificity relative to RT-PCR on a 
combined oro-/nasopharyngeal sample were calculated. Feasibility was evaluated by observer and participant 
questionnaires. 
Results: Among 146 symptomatic adults, 40 (27.4%) were RT-PCR-positive for SARS-CoV-2. Sensitivity with self- 
testing was 82.5% (33/40; 95% CI 68.1–91.3), and 85.0% (34/40; 95% CI 70.9–92.9) with professional testing. 
At high viral load (≥7.0 log10 SARS-CoV-2 RNA copies/ml), sensitivity was 96.6% (28/29; 95% CI 82.8–99.8) for 
both self- and professional testing. Deviations in sampling and testing were observed in 25 out of the 40 PCR- 
positives. Most participants (80.9%) considered the Ag-RDT as easy to perform. 
Conclusion: Laypersons suspected for SARS-CoV-2 infection were able to reliably perform the Ag-RDT and test 
themselves. Procedural errors might be reduced by refinement of the instructions for use or the product design/ 
procedures. Self-testing allows more wide-spread and frequent testing. Paired with the appropriate information 
of the public about the benefits and risks, self-testing may have significant impact on the pandemic.   
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1. Background 
Antigen-detecting rapid diagnostic tests (Ag-RDTs) for SARS-CoV-2 
have been widely recommended as a complement to RT-PCR [1]. 
Recent studies have shown the equivalence of anterior nasal, nasal 
mid-turbinate (NMT), and nasopharyngeal (NP) sampling, and estab-
lished the feasibility of self-sampling for a WHO-listed SARS-CoV-2 
Ag-RDT [2–4]. Considering the ease-of-use in performing the test, 
self-testing is a feasible option. In Germany, first SARS-CoV-2 Ag-RDTs 
received special approvals for self-administration by laypersons on 24 
February 2021 [5]. 
2. Methods 
We conducted a manufacturer-independent prospective study of 
diagnostic accuracy, user acceptability and feasibility of an Ag-RDT 
when performed by patients themselves, with using a self-collected 
NMT sample. For comparison, professional NP-sampling with testing 
on Ag-RDT was performed on the same participant as well as combined 
oropharyngeal (OP)/NP-sampling for RT-PCR as a reference [2]. 
The study took place at the ambulatory SARS-CoV-2 testing facility 
of Charité - Universitätsmedizin Berlin, from 30 November to 11 
December 2020. Participants eligible for inclusion were adults with high 
suspicion of SARS-CoV-2 infection. Participants had to be able to un-
derstand the written instructions in German or English, defined as a 
minimum Common European Framework of Reference for Languages 
(CEFR) level of B2 (upper intermediate). Participants were enrolled 
according to laboratory capacity in a consecutive series. 
The Ag-RDT evaluated was the STANDARD Q COVID-19 Ag Test (SD 
Biosensor, Korea), which is also distributed by Roche [6]. The test was 
chosen in consultation with the Foundation of Innovative New Di-
agnostics based on data on accuracy and ease-of-use. The NP-sampling 
and nasal sampling kits were provided with differing flocked swabs, 
whereby the nasal swab used for self-sampling is less flexible with a 
larger sampling surface [4]. The participants received written and 
illustrated instructions in German or English, adapted from the manu-
facturer’s instructions for use. Participants performed the procedures in 
a separate room without time restrictions. The procedures were 
observed by a study physician, without answering questions or 
providing corrections. The ease of use was evaluated with participant 
and observer questionnaires. 
NMT self-sampling (both sides) was followed by professional NP- 
sampling (through one nostril) for Ag-RDTs and combined OP/NP- 
sampling (through the other nostril) for RT-PCR. The Ag-RDTs were 
performed directly after sampling at point-of-care by participants and 
trained study physicians. 
All Ag-RDT results were interpreted by two blinded study physicians 
with a semi-quantitative assessment, in addition to the participant’s 
interpretation of the self-test [4]. A minimum of 30 positive NP or NMT 
samples according to Ag-RDT was set, which is recommended by the 
WHO Emergency Use Listing Procedure to demonstrate sample type 
equivalency [7]. 
3. Results 
After exclusion of 4 participants (n = 3 not fulfilling the CEFR min-
imum language criterion, n = 1 lost PCR specimen), 146 adults were 
included in the analysis (see Supplementary Figure S1). Of these, 40 
participants (27.4%) tested positive by RT-PCR. Mean age was 35 years 
(Standard Deviation [SD] 11.5), and 51.4% were female. All participants 
were symptomatic at the time of presentation, with a mean duration of 
3.4 days (SD 2.0) post symptom onset. Previous use of any RDTs and/or 
laboratory and/or home-test experience was reported by 29 participants 
(20.4%). A higher education degree was present in 84 (59.6%) partici-
pants. Thirty-eight participants (26.6%) were not native German or 
English speakers (see Supplementary Table S2). 
Self-testing (including self-read-out) yielded a sensitivity of 82.5% 
(33/40 RT-PCR positives detected; 95% CI 68.1–91.3) and a specificity 
of 100% (104/104; CI 96.5–100) compared to RT-PCR (Table 1). The 
sensitivity with professional Ag-RDT testing was 85.0% (34/40; CI 
70.9–92.9) and specificity was 99.1% (105/106; CI 94.8–99.5). In pa-
tients with high viral load (≥7.0 log10 SARS-CoV-2 RNA copies/ml) the 
sensitivity was 96.6% (28/29; CI 82.8–99.8) for both self-testing and 
professional testing. The positive percent agreement between self- 
testing and professional testing on Ag-RDT was 91.4% (32/35; CI 
77.6–97.0); the negative percent agreement was 99.1% (108/109; CI 
95.0–100). 
One patient with a positive self-test had falsely interpreted his result 
as negative. Regarding divergent results, there was one participant 
yielding a false-negative result with self-testing who performed the test 
according to instructions, and one false-negative result with professional 
testing despite a high viral load. In the latter patient, NP-sampling was 
not optimal due to poor tolerance, which occurs rather frequently in 
clinical practice. 
Inter-rater reliability for the double read-out of the self-test by the 
participant and the study physician was very high (kappa 0.98) and 
close to that of two study physicians interpreting the self-test (kappa 1) 
or the professionally performed test (kappa 0.98). 
Deviations of self-sampling included a more vertically-directed angle 
for sampling (23%), incorrect depth of insertion of the swab (4% too 
superficial, 10% too deep), reduced intensity of swabbing (as to duration 
24%, rotations 10% and rubbing 42%) and unilateral NMT-sampling 
(6%). One intervention by the study physician was necessary because 
of a possible risk of injury when the patient tried to insert the swab 
upside down into the nose. 
Deviations of self-testing were observed for the specimen extraction 
(less stirring of the swab 4%, inadequate tube squeezing while stirring 
35% and while removing the swab 33%). Furthermore, it proved diffi-
cult to apply exactly 4 drops to the sample well of the test device (27% 
applying more, 4% less). Several drops coming out at once was the main 
problem (see Supplementary Table S3). 
Participants pointed out that their test performance may have been 
impaired by nervousness (3%), fever or dizziness, poor concentration, 
feeling cold, aversion to self-sampling, language barrier and limited fine 
motor skills (1% each). On a scale from 1 (easy) to 5 (difficult), 114 
(81%) participants stated that the test was easy to perform (scale 1/2); 
23 (16%) found it medium easy/difficult (scale 3), and 4 (3%) difficult 
(scale 4). 
4. Discussion 
The data presented here demonstrates the feasibility and accuracy of 
self-testing in an unselected population and lay the ground for potential 
broader use. Self-testing with Ag-RDTs could not only alleviate over-
stretched RT-PCR capacity and medical personnel, but also may result in 
increased access to frequent testing and significant impact on the 
pandemic [8,9]. If implemented for society at large, recent modeling 
data suggest that repeated screening for SARS-CoV-2, combined with 
immediate reporting, isolation, and quarantine, can greatly reduce viral 
transmission. In this model, test sensitivity is of minor importance [8]. 
However, self-testing should be accompanied by widespread public 
campaigns informing about limited sensitivity, the importance of com-
plementary hygiene measures, e.g., mask use, physical distancing, and 
the necessity of self-quarantine in case of a positive test. Reporting re-
quirements in positive cases should be clarified. As long as Ag-RDTs test 
capacities are limited, deployment must be prioritized, also with a 
global perspective. Individually, Ag-RDT self-testing could contribute to 
resumption of a certain degree of normal life, e.g., self-testing could be 
done before visiting nursing homes. 
The study is limited as it was performed in a single center. Patients 
were rather young and educated. The generalizability of the findings and 
applicability to settings with different prevailing patient characteristics 
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needs to be confirmed. 
In conclusion, we demonstrate that symptomatic laypersons can 
reliably perform a SARS-CoV-2 lateral-flow Ag-RDT and test themselves. 
Procedural errors might be reduced by refinement of the Ag-RDTs for 
self-testing, such as modified instructions for use or product design/ 
procedures. Paired with the appropriate information of the public about 
the benefits and risks, self-testing may have significant impact on the 
pandemic. 
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Table 1 
Antigen-RDT self-testing (NMT sample) with self-readout and professional readout of the result, as well as professional testing (NP sample) in RT-PCR positive out-
patients from combined OP/NP swab. Ct-values and viral loads of the paired RT-PCR samples are shown as well as the duration of symptoms. Relevant protocol 
deviations in the self-test are noted.  
No. Ag-RDT self-use (NMT) Ag-RDT prof.-use (NP) RT-PCR (OP/NP) Days of Symptoms Deviations in Ag-RDT self-use  
self-readout prof-readout Ct value Viral load1 
1 pos. pos. (+++) pos. (+++) 14.822 9.57 2 sampling4 
2 pos. pos. (+++) pos. (+++) 18.293 9.30 2 extraction5 
3 pos. pos. (+++) pos. (+++) 16.202 9.16 2 extraction5 
4 pos. pos. (+++) pos. (+++) 16.342 9.12 3 extraction5 
5 pos. pos. (+++) pos. (+++) 16.892 8.96 1 sampling4, extraction5 
6 pos. pos. (+++) pos. (+++) 19.513 8.94 2 extraction5, volume6 
7 pos. pos. (+++) pos. (+++) 17.432 8.80 2  
8 pos. pos. (+++) pos. (+++) 20.303 8.71 4  
9 pos. pos. (++) pos. (+++) 17.742 8.70 3  
10 pos. pos. (+++) pos. (+++) 20.353 8.69 4  
11 pos. pos. (+++) pos. (+++) 17.942 8.64 3 extraction5, volume6 
12 pos. pos. (+++) pos. (+++) 20.723 8.58 1  
13 pos. pos. (++) neg. 18.502 8.48 1 sampling4, extraction5 
14 pos. pos. (+++) pos. (+++) 21.343 8.40 3  
15 pos. pos. (+++) pos. (+++) 18.962 8.34 7 extraction5, volume6 
16 pos. pos. (+++) pos. (+++) 19.262 8.25 2 sampling4, extraction5 
17 pos. pos. (+++) pos. (+++) 19.292 8.24 3  
18 pos. pos. (+++) pos. (+++) 21.943 8.22 1 extraction5 
19 pos. pos. (+++) pos. (+++) 19.482 8.19 4  
20 pos. pos. (+++) pos. (+++) 19.492 8.18 4 sampling4 
21 pos. pos. (+++) pos. (+++) 19.522 8.17 4 sampling4, extract.5, vol.6 
22 pos. pos. (+++) pos. (+++) 19.742 8.11 2 sampling4, extraction5 
23 pos. pos. (+++) pos. (+++) 19.952 8.05 3  
24 pos. pos. (++) pos. (+++) 20.672 7.83 3 extraction5 
25 pos. pos. (+++) pos. (+++) 23.713 7.70 6 sampling4 
26 pos. pos. (++) pos. (+++) 23.993 7.62 3 extraction5, volume6 
27 pos. pos. (+++) pos. (+++) 21.982 7.44 7  
28 pos. pos. (++) pos. (+++) 24.893 7.35 8 sampling4, extraction5 
29 neg. pos. (++) pos. (++) 22.672 7.24 3 read-out7 
30 pos. pos. (++) pos. (++) 24.862 6.59 7 sampling4 
31 neg. neg. pos. (+) 25.072 6.52 5  
32 pos. pos. (+++) pos. (++) 28.583 6.26 8  
33 neg. neg. neg. 27.052 5.94 1  
34 pos. pos. (++) pos. (+) 29.712 5.15 5 extraction5, volume6 
35 pos. pos. (++) pos. (+) 30.032 5.05 7 extraction5 
36 pos. pos. (+) pos. (++) 30.282 4.98 7 sampling4, extraction5 
37 neg. neg. neg. 35.693 4.15 7  
38 neg. neg. neg. 33.292 3.91 14 sampling4, extract.5, vol.6 
39 neg. neg. neg. 34.542 3.71 8  
40 neg. neg. neg. 34.992 3.41 14 extraction5  
Sensitivity 33/40 (82.5%) Sensitivity 34/40 (85.0%) Sensitivity 34/40 (85.0%)      
1 log10 SARS-CoV-2 RNA copies/ml;  
2 TIB Molbiol assay, E-gene target;  
3 roche cobas SARS-CoV-2 assay (E-gene, T2 target);  
4 sampling of possible reduced quality (unilateral, short, different position);  
5 extraction of possible reduced quality related to stirring of the swab or squeezing of the buffer tube;  
6 vol = volume: incorrect number of drops applied on the test device;  
7 read-out: misinterpretation of the test-result.  
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